Welcome to our dedicated page for Protagonist Therapeutics news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Therapeutics stock.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to discover and develop novel peptide-based drugs. The company's primary focus is on creating first-in-class oral targeted therapies that inhibit biological pathways currently addressed by injectable antibody drugs. This innovative approach aims to treat significant unmet medical needs, particularly in the areas of inflammatory bowel disease (IBD) and other autoimmune diseases.
Protagonist's lead peptide product candidates, PTG-100 and PTG-200, are designed to transform treatment paradigms for conditions such as ulcerative colitis and Crohn's disease. PTG-100, an oral peptide alpha-4-beta-7 integrin antagonist, is in a global Phase 2b clinical trial for moderate-to-severe ulcerative colitis. PTG-200, a first-in-class oral interleukin-23 receptor antagonist, is also progressing through clinical trials.
Another key asset, JNJ-2113 (formerly PN-235), achieved primary and secondary endpoints in the Phase 2b FRONTIER 1 trial for moderate-to-severe plaque psoriasis. This drug is part of an extensive clinical development program, including multiple Phase 3 studies under the ICONIC program. JNJ-2113 is also being evaluated in a Phase 2b ANTHEM-UC study for ulcerative colitis.
Protagonist's pipeline also includes Rusfertide (PTG-300), an injectable hepcidin mimetic currently in Phase 3 development for polycythemia vera. The REVIVE Phase 2 study demonstrated that rusfertide effectively maintains hematocrit control and reduces the need for phlebotomies in patients.
The company has established significant partnerships to further its clinical programs. Notably, Protagonist collaborates with Johnson & Johnson and Takeda Pharmaceuticals to co-develop and co-commercialize its lead candidates, expanding its reach and impact in the biopharmaceutical landscape.
Protagonist continues to drive innovation with its ongoing discovery efforts, aiming to develop additional oral peptides targeting validated biological pathways. With a robust pipeline and strategic collaborations, Protagonist Therapeutics is poised to make substantial contributions to the treatment of autoimmune and hematological diseases.
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) has priced an underwritten public offering of 4,761,904 shares of common stock at $21.00 each, targeting $100 million in gross proceeds before expenses. The offering will close around December 15, 2020, subject to customary conditions. The underwriters have a 30-day option to buy an additional 714,285 shares. Joint book-running managers include J.P. Morgan, SVB Leerink, Piper Sandler, and BMO Capital Markets. A registration statement was filed with the SEC on the same day as the announcement.
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) announced a public offering of $100 million of its common stock, with the possibility of granting underwriters a 30-day option to purchase an additional 15%. The offering is subject to market conditions, and there is no guarantee on its completion or the size of the offering. J.P. Morgan, SVB Leerink, Piper Sandler, and BMO Capital Markets are the joint book-running managers. A shelf registration statement was filed with the SEC on December 10, 2020. Investors are advised to consult the SEC filings for detailed information.
Protagonist Therapeutics (Nasdaq:PTGX) released findings from a significant analysis on treatment patterns for polycythemia vera, indicating that existing therapies fail to adequately control hematocrit levels in most patients. Specifically, only 22% maintained levels below the recommended 45%, with nearly 49% experiencing levels exceeding 50% during the observation. The results highlight an unmet need for effective treatment options in this patient population, with a Phase 2 study of PTG-300 currently enrolling participants. These findings will be discussed at the ASH 2020 meeting.
Protagonist Therapeutics (Nasdaq: PTGX) announced promising Phase 2 study results for PTG-300, aimed at treating polycythemia vera (PV). The study showed that most of the 18 patients treated could eliminate therapeutic phlebotomies while maintaining hematocrit levels below 45%. Additionally, PTG-300 demonstrated the ability to reverse iron deficiency and reduce symptom burden over time. The treatment was well tolerated with minimal adverse effects. Protagonist plans to share these findings with regulatory authorities and expects to complete patient enrollment by mid-2021.
Protagonist Therapeutics announced that its candidate PTG-300 received FDA Fast Track designation for treating polycythemia vera, a rare blood disorder. This designation could expedite the development process, including more frequent FDA interactions. PTG-300 is a synthetic hepcidin mimetic shown to significantly reduce phlebotomy needs in ongoing Phase 2 trials, which are expected to complete enrollment by mid-2021. The FDA's Fast Track program aims to accelerate therapies addressing serious conditions and unmet medical needs.
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) announced on December 1, 2020, the issuance of an inducement award to Michelle Landolfi, Ph.D., its new Vice President of Regulatory Affairs. The award includes an option to purchase 50,000 shares at an exercise price of $24.16, with a four-year vesting schedule. This grant follows Nasdaq Marketplace Rule 5635(c)(4) and was approved by the company's compensation committee. Protagonist specializes in developing peptide-based therapeutics for unmet medical needs, with ongoing projects for polycythemia vera and inflammatory bowel disease.
Protagonist Therapeutics (Nasdaq:PTGX) announced a conference call on December 9, 2020, at 8:30 a.m. EST to provide an R&D and corporate update. The management team will be joined by Dr. Andrew Kuykendall from Moffitt Cancer Center, who is involved in the PTG-300 Phase 2 study. Interested parties can join the call by dialing 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and referencing conference ID 8794865. The call will also be available via webcast on the company's website.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced that its CEO, Dinesh V. Patel, Ph.D., will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference from November 30 to December 3, 2020. Registered attendees can view the presentation on the conference site until December 3, and it will also be accessible via the company's Investors section starting November 30. Protagonist focuses on developing peptide-based therapeutics for unmet medical needs, with three clinical-stage assets targeting blood disorders and inflammatory bowel disease.
Protagonist Therapeutics (NASDAQ:PTGX) announced that its President and CEO, Dinesh V. Patel, will join a fireside chat at the Jefferies Virtual 2020 London Healthcare Conference. The event is scheduled for November 17, 2020, at 5:35 p.m. GMT (12:35 p.m. EST). A live and archived webcast will be accessible via the company's website and the provided links.
Protagonist is a clinical-stage biopharmaceutical company focusing on developing peptide-based therapeutics for significant medical needs, currently advancing three clinical-stage assets.
Protagonist Therapeutics (PTGX) reported its third-quarter 2020 financial results, highlighting ongoing Phase 2 clinical studies for its assets PTG-300, PN-943, and PTG-200.
Notably, PTG-300 received orphan designation from the EMA, with full enrollment expected by mid-2021 and a pivotal study slated for the second half of 2021.
In Q3 2020, Protagonist raised $25.3 million through its ATM program and reported revenue of $13.1 million, up from $4.1 million in Q3 2019. Despite a net loss of $7.8 million, losses narrowed from $16.4 million in the same period last year.
FAQ
What is the current stock price of Protagonist Therapeutics (PTGX)?
What is the market cap of Protagonist Therapeutics (PTGX)?
What is Protagonist Therapeutics' main focus?
What are PTG-100 and PTG-200?
What is JNJ-2113?
What is rusfertide (PTG-300)?
Who are Protagonist's collaboration partners?
What recent achievements has Protagonist announced?
What is Protagonist's proprietary technology platform?
What are the latest developments in Protagonist's clinical trials?
What is the status of the rusfertide Phase 3 VERIFY trial?
Where can I find more information about Protagonist's drug candidates and clinical studies?
